Theriva Biologics, Inc.'s TOVX stock has seen an increase in trading following the news of being named a finalist for Merck's KGaA's EMEA Advance Biotech Grant. This recognition has resulted in a rise of 31.6% in the company's stock, with current trading at $1.92 per share. The opportunity for finalists to present their projects to a panel of judges at the prestigious BIO Europe 2024 event in Stockholm, Sweden, provides a significant platform for Theriva, especially with their focus on VCN-01 and its ongoing clinical trial for pancreatic cancer.
During the presentation at the upcoming event, Theriva's General Director of EU Subsidiary, Manel Cascalló, will offer insights into VCN-01 and its role in the Phase 2b clinical trial alongside standard chemotherapy for metastatic pancreatic cancer. The chance to secure financial support and receive guidance on commercialization from M Ventures adds to the appeal of winning the grant. Additionally, winning this grant could open doors for Theriva to navigate the complexities of bringing their product to the market successfully. Investors have various options to access Theriva's stock, not limited to purchasing shares through a brokerage platform, but also through ETFs that track the health care sector, providing exposure to diverse companies within the industry.